634 reports of this reaction
1.3% of all HALOPERIDOL LACTATE reports
#20 most reported adverse reaction
ELECTROCARDIOGRAM QT PROLONGED is the #20 most commonly reported adverse reaction for HALOPERIDOL LACTATE, manufactured by Fresenius Kabi USA, LLC. There are 634 FDA adverse event reports linking HALOPERIDOL LACTATE to ELECTROCARDIOGRAM QT PROLONGED. This represents approximately 1.3% of all 50,066 adverse event reports for this drug.
Patients taking HALOPERIDOL LACTATE who experience electrocardiogram qt prolonged should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ELECTROCARDIOGRAM QT PROLONGED is a less commonly reported adverse event for HALOPERIDOL LACTATE, but still significant enough to appear in the safety profile.
In addition to electrocardiogram qt prolonged, the following adverse reactions have been reported for HALOPERIDOL LACTATE:
The following drugs have also been linked to electrocardiogram qt prolonged in FDA adverse event reports:
ELECTROCARDIOGRAM QT PROLONGED has been reported as an adverse event in 634 FDA reports for HALOPERIDOL LACTATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ELECTROCARDIOGRAM QT PROLONGED accounts for approximately 1.3% of all adverse event reports for HALOPERIDOL LACTATE, making it a notable side effect.
If you experience electrocardiogram qt prolonged while taking HALOPERIDOL LACTATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.